TY - JOUR
T1 - Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide
AU - Kunikata, Hiroshi
AU - Yasuda, Masayuki
AU - Aizawa, Naoko
AU - Tanaka, Yuji
AU - Abe, Toshiaki
AU - Nakazawa, Toru
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Publication of this article was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology , Tokyo, Japan (Grant-in-Aid for Young Scientists [B] 22791648 ). Contributions of authors: involved in design and conduct of the study (H.K., T.N.); collection, management, analysis, and interpretation of the data (H.K., M.Y., N.A., Y.T.); and preparation, review, or approval of the manuscript (T.A., T.N.).
PY - 2013/6
Y1 - 2013/6
N2 - Purpose: To investigate the role of intravitreal injection of triamcinolone acetonide (IVTA) in preventing photoreceptor apoptosis in eyes with rhegmatogenous retinal detachment (RRD) by measuring cytokine levels in the aqueous humor before and after IVTA. Design: Prospective, nonrandomized, interventional case series. Methods: setting: Institutional. patients: Nineteen eyes of 19 consecutive patients with RRD. intervention: All 19 eyes underwent IVTA 1 day before 25-gauge vitrectomy. Seventeen eyes free of retinal vascular disease served as controls. main outcome measure: Both baseline and 1 day post-IVTA measurements were made of the relative concentrations of 15 soluble factors (3 cytokines, 7 chemokines, and 5 growth factors). The associations with clinical findings, including macular status, were then analyzed. Results: Elevated monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1β (MIP-1β), and interferon γ-induced protein 10 (IP-10) in eyes with RRD were significantly reduced after IVTA. MCP-1 levels were significantly correlated with MIP-1β and IP-10 before and after IVTA. The decreases in MCP-1, MIP-1β, and IP-10 were also closely correlated to each other. Both before and after IVTA, MCP-1 was higher in eyes with macula-off RRD than in eyes with macula-on RRD. Conclusions: IVTA suppressed elevated levels of intraocular MCP-1, MIP-1β, and IP-10 in eyes with RRD. The decrease in the aqueous levels of each of these factors was significantly correlated with the others. In addition to MCP-1, MIP-1β and IP-10 might potentially be additional target molecules for RRD therapy.
AB - Purpose: To investigate the role of intravitreal injection of triamcinolone acetonide (IVTA) in preventing photoreceptor apoptosis in eyes with rhegmatogenous retinal detachment (RRD) by measuring cytokine levels in the aqueous humor before and after IVTA. Design: Prospective, nonrandomized, interventional case series. Methods: setting: Institutional. patients: Nineteen eyes of 19 consecutive patients with RRD. intervention: All 19 eyes underwent IVTA 1 day before 25-gauge vitrectomy. Seventeen eyes free of retinal vascular disease served as controls. main outcome measure: Both baseline and 1 day post-IVTA measurements were made of the relative concentrations of 15 soluble factors (3 cytokines, 7 chemokines, and 5 growth factors). The associations with clinical findings, including macular status, were then analyzed. Results: Elevated monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1β (MIP-1β), and interferon γ-induced protein 10 (IP-10) in eyes with RRD were significantly reduced after IVTA. MCP-1 levels were significantly correlated with MIP-1β and IP-10 before and after IVTA. The decreases in MCP-1, MIP-1β, and IP-10 were also closely correlated to each other. Both before and after IVTA, MCP-1 was higher in eyes with macula-off RRD than in eyes with macula-on RRD. Conclusions: IVTA suppressed elevated levels of intraocular MCP-1, MIP-1β, and IP-10 in eyes with RRD. The decrease in the aqueous levels of each of these factors was significantly correlated with the others. In addition to MCP-1, MIP-1β and IP-10 might potentially be additional target molecules for RRD therapy.
UR - http://www.scopus.com/inward/record.url?scp=84877767687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877767687&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2013.01.013
DO - 10.1016/j.ajo.2013.01.013
M3 - Article
AN - SCOPUS:84877767687
SN - 0002-9394
VL - 155
SP - 1028-1037.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 6
ER -